Matter, Christian M.

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes

Knuuti, J., Wijns, W., Saraste, A., Capodanno, D., Barbato, E., Funck-Brentano, C., Prescott, E., Storey, R. F., Deaton, C., Cuisset, T., et al. (2020) · European Heart Journal

Coronary Interventions and DiagnosticsAcute Myocardial Infarction Research

Cited by 7,166

Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease

Besler, C., Heinrich, K., Rohrer, L., Doerries, C., Riwanto, M., Shih, D. M., Chroni, A., Yonekawa, K., Stein, S., Schaefer, N., et al. (2011) · Journal of Clinical Investigation

Nitric Oxide and Endothelin EffectsParaoxonase enzyme and polymorphisms

Cited by 535

Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors

Li, X. S., Obeid, S., Klingenberg, R., Gencer, B., Mach, F., Räber, L., Windecker, S., Rodondi, N., Nanchen, D., Muller, O., et al. (2017) · European Heart Journal

Gut microbiota and healthAcute Myocardial Infarction Research

Cited by 479

The Sirt1 activator SRT3025 provides atheroprotection in Apoe−/− mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression

Miranda, M. X., van Tits, L. J., Lohmann, C., Arsiwala, T., Winnik, S., Tailleux, A., Stein, S., Gomes, A. P., Suri, V., Ellis, J. L., et al. (2015) · European Heart Journal

Cholesterol and Lipid MetabolismSirtuins and Resveratrol in Medicine

Cited by 153

Eligibility for PCSK9 inhibitors according to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines after acute coronary syndromes

Gencer, B., Koskinas, K. C., Räber, L., Karagiannis, A., Nanchen, D., Auer, R., Carballo, D., Carballo, S., Klingenberg, R., Heg, D., et al. (2017) · Journal of the American Heart Association

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 35

Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial

Koskinas, K. C., Windecker, S., Buhayer, A., Gencer, B., Pedrazzini, G., Mueller, C., Cook, S., Muller, O., Matter, C. M., Räber, L., et al. (2018) · Clinical Cardiology

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 26

Dietary α-linolenic acid increases the platelet count in ApoE−/− mice by reducing clearance

Stivala, S., Reiner, M. F., Lohmann, C., Lüscher, T. F., Matter, C. M., & Beer, J. H. (2013) · Blood

Platelet Disorders and TreatmentsFatty Acid Research and Health

Cited by 21

T-cell activation and fibroblastic BMP4-Gremlin dysregulation indicate disease severity in acute myocarditis

Joachimbauer, A., Perez-Shibayama, C., Payne, E., Hanka, I., Stadler, R., Papadopoulou, I., Rickli, H., Mäder, M. T., Borst, O., Zdanyte, M., et al. (2026) · medRxiv

Viral Infections and Immunology ResearchCardiac Fibrosis and Remodeling

Cited by 1